Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bimagrumab + tirzepatide
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
Bimagrumab + tirzepatide is an investigational combination therapy for obesity and weight management. Bimagrumab is a fully human monoclonal antibody that targets activin type II receptors, blocking ligands such as myostatin, activins, and GDF11 to promote skeletal muscle growth and reduce fat mass. Tirzepatide is a synthetic peptide that acts as a dual agonist at the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide 1 (GLP-1) receptor, stimulating insulin secretion in a glucose-dependent manner, reducing glucagon levels, delaying gastric emptying, decreasing food intake, and promoting weight loss. The combination aims to leverage complementary mechanisms—bimagrumab’s direct effects on adipose tissue and muscle with tirzepatide’s incretin-based metabolic actions—to enhance efficacy in treating obesity[1][4][7][8].
- Other names
- None
02
Targets
ACVR2B (Activin receptor type IIB)GIPR (Gastric inhibitory polypeptide receptor)ACVR2A (Activin receptor type 2A)GLP1R (GLP-1R)
Beyond the preview
Go deeper on bimagrumab + tirzepatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bimagrumab + tirzepatide.